← All trials
NCT06272695
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2024
- Primary completion
- Jun 15, 2025
- Completion date
- Jun 15, 2025
- First posted
- Feb 22, 2024
- Last posted
- Apr 10, 2024
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- REMD Biotherapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.